S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
NASDAQ:XGN

Exagen (XGN) Stock Price, News & Analysis

$1.43
-0.05 (-3.38%)
(As of 04/15/2024 ET)
Today's Range
$1.42
$1.47
50-Day Range
$1.42
$2.25
52-Week Range
$1.33
$3.92
Volume
19,419 shs
Average Volume
41,329 shs
Market Capitalization
$24.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Exagen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
319.6% Upside
$6.00 Price Target
Short Interest
Healthy
0.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.62mentions of Exagen in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$24,417 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.46) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.45 out of 5 stars

Medical Sector

101st out of 929 stocks

Medical Laboratories Industry

4th out of 20 stocks

XGN stock logo

About Exagen Stock (NASDAQ:XGN)

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN Stock Price History

XGN Stock News Headlines

Short Interest in Exagen Inc. (NASDAQ:XGN) Increases By 294.2%
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript
Exagen Full Year 2023 Earnings: Beats Expectations
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
Here's what to expect from Exagen's earnings
Exagen reports Q4 results
XGN Apr 2024 2.500 put
See More Headlines
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/15/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:XGN
Fax
N/A
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+316.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,690,000.00
Pretax Margin
-45.02%

Debt

Sales & Book Value

Annual Sales
$52.55 million
Book Value
$1.33 per share

Miscellaneous

Free Float
10,893,000
Market Cap
$24.83 million
Optionable
Optionable
Beta
1.19
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Tina S. Nova Ph.D. (Age 70)
    Executive Chairman of the Board of Directors
    Comp: $65k
  • Mr. John Aballi (Age 39)
    CEO, President & Director
    Comp: $558.84k
  • Mr. Kamal Adawi M.S. (Age 45)
    MBA, CFO & Corporate Secretary
    Comp: $483.28k
  • Ryan Douglas
    Investors Relations Officer
  • Mr. John Wegener (Age 55)
    Senior Vice President of Sales and Marketing
  • Dr. Andrew L. Concoff FACR
    M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
  • Dr. Michael I. Nerenberg M.D. (Age 69)
    Chief Medical Officer

XGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Exagen stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XGN shares.
View XGN analyst ratings
or view top-rated stocks.

What is Exagen's stock price target for 2024?

2 Wall Street research analysts have issued 1-year target prices for Exagen's shares. Their XGN share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 319.6% from the stock's current price.
View analysts price targets for XGN
or view top-rated stocks among Wall Street analysts.

How have XGN shares performed in 2024?

Exagen's stock was trading at $1.99 at the start of the year. Since then, XGN shares have decreased by 28.1% and is now trading at $1.43.
View the best growth stocks for 2024 here
.

Are investors shorting Exagen?

Exagen saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 20,500 shares, an increase of 294.2% from the March 15th total of 5,200 shares. Based on an average trading volume of 43,900 shares, the short-interest ratio is presently 0.5 days. Currently, 0.3% of the company's shares are short sold.
View Exagen's Short Interest
.

When is Exagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our XGN earnings forecast
.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) released its earnings results on Monday, March, 18th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.02. The company had revenue of $13.77 million for the quarter, compared to analyst estimates of $11.43 million. Exagen had a negative net margin of 45.08% and a negative trailing twelve-month return on equity of 80.28%. During the same quarter in the previous year, the firm earned ($0.58) earnings per share.

What guidance has Exagen issued on next quarter's earnings?

Exagen updated its FY 2024 earnings guidance on Monday, March, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.0 million-$54.0 million, compared to the consensus revenue estimate of $54.1 million.

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.

When did Exagen IPO?

Exagen (XGN) raised $50 million in an initial public offering on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XGN) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners